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Combination of chemotherapy and PD-1 blockade
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Here, we developed an unbiased, functional target-discovery platform to identify immuno-
genic proteins from primary non-small cell lung cancer (NSCLC) cells that had been induced
to apoptosis by cisplatin (CDDP) treatment in vitro, as compared with their live counterparts.
Among the multitude of proteins identified, some of them were represented as fragmented
proteins in apoptotic tumor cells, and acted as non-mutated neoantigens (NM-neoAgs).
Indeed, only the fragmented proteins elicited effective multi-specific CD4+ and CD8+ T cell
responses, upon a chemotherapy protocol including CDDP. Importantly, these responses
further increased upon anti-PD-1 therapy, and correlated with patients’ survival and
decreased PD-1 expression. Cross-presentation assays showed that NM-neoAgs were
unveiled in apoptotic tumor cells as the result of caspase-dependent proteolytic activity of
cellular proteins. Our study demonstrates that apoptotic tumor cells generate a repertoire of
immunogenic NM-neoAgs that could be potentially used for developing effective T cell-based
immunotherapy across multiple cancer patients.
https://doi.org/10.1038/s42003-020-0811-x OPEN
1 Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, 00161 Rome, Italy. 2 Dipartimento di Medicina Molecolare, Sapienza
Università di Roma, 00161 Rome, Italy. 3 Dipartimento di Scienze Radiologiche, Oncologiche e Anatomo Patologiche, Oncologia Medica, Università di Roma,
00161 Rome, Italy. 4 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy. 5 IRCCS Neuromed,
Pozzilli, Isernia, Italy. 6 Dipartimento di Scienze e Biotecnologie Medico-Chirurgiche, Sapienza Università di Roma - Polo Pontino, 04100 Latina, Italy. 7 UOC
Oncologia Universitaria, ASL Latina (distretto Aprilia), Sapienza Università di Roma, Via Giustiniano snc, 04011 Aprilia, Latina, Italy. 8 Center for Life Nano
Science@Sapienza, Istituto Italiano di Tecnologia, 00161 Rome, Italy. 9 Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer
Institute, Rome, Italy. 10Medical Oncology 1, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 11 Unit of Pathology, IRCCS-Regina Elena National
Cancer Institute, Rome, Italy. 12 Thoracic Surgery Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 13 Istituto Pasteur - Fondazione Cenci
Bolognetti, 00185 Rome, Italy. 14These authors contributed equally: Alessio Grimaldi, Ilenia Cammarata. ✉email: vincenzo.barnaba@uniroma1.it
COMMUNICATIONS BIOLOGY |            (2020) 3:85 | https://doi.org/10.1038/s42003-020-0811-x | www.nature.com/commsbio 1
12
34
56
78
9
0
()
:,;
Lung cancer is the major cause of cancer-related deathworldwide, and non-small-cell lung cancer (NSCLC)accounts for 85% of lung cancer cases, of which lung ade-
nocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)
are the most common subtypes1. Additionally, NSCLC is mole-
cularly heterogeneous, because of the amazing diversity of
somatic genome mutations, including mutations of genes con-
tributing to carcinogenesis (driver genes; e.g., KRAS, EGFR, TP53,
etc.)2, and passenger mutations of genes unrelated to tumor
growth, a large part of which are patient specific (private) and
confers a huge antigenic heterogeneity to various tumors
including NSCLC3,4.
In the past decade, immunotherapy has achieved extraordinary
objective response rates for the treatment of tumors, particularly
by using monoclonal antibodies (mAbs) specific to various inhi-
bitory signaling molecules (immune checkpoints, such as pro-
grammed death-1 [PD-1] or cytotoxic T-lymphocyte antigen-4
[CTLA-4]) that are strongly upregulated by exhausted tumor-
infiltrating lymphocytes5–9. These mAbs (defined as checkpoint
inhibitors) unleash anti-tumor T cells, leading to a reliable
shrinkage of several metastatic tumors. However, checkpoint
inhibitors currently used to target CD8+ T cells (e.g., anti-CTLA-4
and/or anti-PD-1 mAbs) have not been shown to be efficient for
all tumor types and may cause a partial remission in the majority
of tumors. Innovative immunotherapy strategies are in progress,
particularly based on the combination of different approaches,
including new and current inhibitors providing immune check-
point blockade (ICB), as well as tumor vaccines against neoanti-
gens (neoAgs) that are generated as a consequence of the wide
tumor genome mutations4. T cells specific to either public or
private neoAgs, which are encoded by somatic gene mutations, are
not purged by central tolerance10, can migrate in the periphery,
and be of particular relevance to tumor control4,11–18. This con-
clusion is supported by the association between tumor T cell
infiltration and mutational load, or between the expansion of
mutated neoAg-specific T cells and the reinvigoration of anti-
tumor T cell immunity following ICB14,17,19. However, despite the
high mutational burden and the huge tumor T cell infiltration in
several tumors including NSCLC, the frequencies of the related
neoAg-specific T cells are relatively very low20–23. In the light of
these evidences, it is possible that a consistent proportion of
tumor-associated T cells may be specific to non-mutated (NM)-
neoAgs generated by various forms of protein modifications
occurring at post-transcriptional level, such as protein splicing24,
dysregulated phosphorylation or glycosylation25–27, proteasome
generation of spliced peptides28, peptide citrullination29, impaired
peptide processing in TAP-deficient tumor cells30, or proteasomal
degradation of defective ribosomal products (DRiPs)31. These
NM-neoAgs may provide rational targets for cancer immu-
notherapy, because they should not be expressed or expressed at
concentrations that are not enough to delete specific T cells in the
thymus.
Potentially, also chemotherapy or radiotherapy may generate
immunogenic NM-neoAgs in dying tumor cells, through their
capacity to induce immunogenic cell death (ICD)32–35. ICD can
enable tumor cells to provide both novel antigenic signals,
including caspase-cleaved fragmented proteins during
apoptosis36,37, and costimulatory signals, such as a distinct sets of
damage-associated molecular patterns (ATP, calreticulin,
HMGB1, etc.) principally converting tolerogenic into stimulatory
dendritic cells (DCs)32–35,38–42. Then, DCs acquire high cap-
ability to migrate, to phagocytose dying cells, to process more
efficiently caspase-cleaved cellular proteins (i.e., NM-neoAgs),
and to cross-prime CD8+ T cells that can provide tumor
control35,38,41,42, on the one hand, and immunopathology in
various forms of chronic inflammatory diseases, on the other
hand37,43–48. In addition, several studies found that ICD syner-
gizes with ICB therapy to further improve T cell responses against
different tumors, proposing hence the hypothesis that ICD con-
verts tumor cells into endogenous vaccine and boosts the ICB
effects49–54. However, despite the large body of evidences on how
ICD occurs, few evidences have been reported about the nature of
antigens becoming immunogenic upon ICD41,42.
Here, we used stable isotope labeling by amino acids in cell
culture (SILAC)-based mass spectrometry (MS) to quantitatively
compare the proteome of primary NSCLC cells that had been
made apoptotic by cisplatin (CDDP) treatment in vitro and their
live counterparts. The expression of a multitude of proteins was
found differently regulated, some of which were represented as
fragmented proteins in CDDP-treated apoptotic (CDDP-ap)
tumor cells, as the result of a caspase-dependent proteolytic
activity. Then, we interrogated memory T cells from NSCLC
patients, to detect whether these fragmented proteins were gen-
erated in tumor cells following chemotherapy-induced apoptosis,
and whether they could act as immunogenic NM-neoAgs capable
of inducing potentially protective anti-tumor immune responses.
Results
Identification of proteome changes in apoptotic NSCLC cells.
SILAC-based MS was used to identify changes in the proteome of
primary NSCLC cells, as previously described55 (Fig. 1). In brief,
primary NSCLC cells (named EpT1Lu line, isolated from a sur-
gery specimen obtained and characterized, as described in
Methods section) (Supplementary Fig. 1) were metabolically
labeled with heavy (13C6-Lys and 13C6-15N4-Arg) isotope med-
ium, and subsequently induced to apoptosis by 0.625 µM CDDP
treatment (72 h) (Fig. 1a). Apoptosis was validated by the con-
sistent upregulation of Annexin V and activated caspase-3 in
CDDP-treated cells (Supplementary Fig. 1). Non-labeled EpT1Lu
cells were grown in light medium (12C6-Lys and 12C6-14N4-Arg)
and maintained in viable condition. Then, apoptotic cells and live
cells were sorted from heavy and light NSCLC populations,
respectively (Fig. 1a). A reverse SILAC experiment (SILAC
reverse), switching heavy and light media, was also performed.
Apoptotic (heavy) and live (light) cells obtained in five inde-
pendent experiments were pooled and lysed, and equal amounts
of proteins from each cell line were mixed (Fig. 1a). One hundred
micrograms of this sample was separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and the
gel lane was cut into 16 sections ranging from 5 to 250 kDa
(Fig. 1b). Proteins from each gel section were digested and
quantified using liquid chromatography (nanoLC) followed by
5800 MALDI-TOF/TOF (matrix-assisted laser desorption/ioni-
zation tandem time-of-flight) analysis. By this procedure, among
the 815 proteins differently expressed between apoptotic (heavy)
and live (light) NSCLC cells, some of them resulted as fragmented
proteins upregulated in apoptotic NSCLC cells (Fig. 1b). To select
fragmented proteins originated by CDDP-dependent apoptosis,
we used the electrophoresis-derived molecular weight (MWexp)
of the protein as the identification constraint. Fragmented pro-
teins were identified on the basis of the evidence that the MWexp
of a polypeptide resulted lower than the theoretical molecular
weight (MWcal) of the corresponding entire protein (Fig. 1b and
Table 1). Comparison between apoptotic (heavy) and live (light)
NSCLC cells in forward SILAC experiments showed that out of a
total of 815 proteins identified and quantified (Supplementary
Data 1 reported in Description of additional supplementary
items), 253 proteins (31%) were found overabundant, 439 (54%)
proteins were found downregulated, whereas 16 (2%) resulted
fragmented proteins upregulated in apoptotic cells (Fig. 1c).
Notably, similar results were found in the reverse SILAC, thus
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highlighting a high reproducibility between the SILAC replicates
(Supplementary Fig. 2a; Supplementary Data 1). Accordingly, 16
and 11 identifications resulting as fragmented proteins in forward
and reverse SILAC experiments, respectively, were found upre-
gulated in apoptotic cells (Table 1; the nature and function of
these proteins are described in Supplementary Notes reported in
Supplementary Informations). Among them, six fragments were
identified in both SILAC experiments (Table 1). Biological
process-based gene ontology (GO) analysis (PANTHER [Protein
ANalysis THrough Evolutionary Relationships], version 14.1) of
upregulated proteins confirmed gene enrichment categories in the
frame of execution phase of apoptosis and apoptotic signaling
pathway (Supplementary Fig. 2b).
To validate the relationship between proteins identified by
SILAC-based proteomics and NSCLC, immunohistochemical
(IHC) analyses were performed in cancer tissues derived from
various patients, by using (commercially) available specific mAbs
that were obtained by immunization with the proactivator
polypeptide (PSAP)325–524, or the N terminal domain of LYRIC
sequences. Both these sequences contained the peptides that were
associated with the related proteins with a confidence of more
than 95% by spectra analyses (Table 1; Supplementary Data 1).
These mAbs detected the related antigenic proteins in both live
and apoptotic NSCLC cells in tumor tissues derived from five
independent patients tested, who were submitted to the surgery
resection upon neo-adjuvant chemotherapy (Supplementary
Fig. 3), but not in tumor tissues from two patients, who were
submitted to the surgery resection without neo-adjuvant
chemotherapy. These data suggest that proteins identified in
freshly isolated NSCLC cells by SILAC-based proteomics are
represented in NSCLC tissue from various patients after
chemotherapy. As expected, anti-PSAP and anti-LYRIC anti-
bodies detected the related proteins considerably more in live
than in apoptotic tumor cells by IHC analysis (Supplementary
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Fig. 1 Identification of proteome in primary apoptotic and live NSCLC cells by SILAC-based MS. a Primary NSCLC cells (EpT1Lu) were either labeled with
heavy (13C6-Lys and 13C6-15N4-Arg) medium or conditioned with light (12C6-Lys and 12C6-14N4-Arg) medium. The heavy isotope-labeled cells were induced
to apoptosis by 0.625 µM CDDP treatment (apoptotic cells). Apoptotic (heavy) and live (light) fractions were sorted and lysed; equal amounts of protein
extracts were mixed in a 1:1 ratio and separated in SDS-PAGE, enzymatically digested, and analyzed with nanoLC-MS/MS. b Mass spectra of two
representative fragmented proteins (“Ras and EF-hand domain-containing protein” and “actin, cytoplasmic 2”) identified in both SILAC forward and
reverse. Both these fragmented proteins were found upregulated in heavy apoptotic cells (and as consequence downregulated in light live cells) and
migrated at the level of gel fractions 15 (MWexp range 5–10 kDa; heavy/light ratio: 15.9134) and 16 (MWexp range 5–10 kDa; heavy/light ratio: 9.4949),
respectively. The expected MWs of the entire forms of these proteins are 82.9 and 41.8 kDa, respectively (Table 1). Name, gene name, accession number,
confidence of identification, sequence of identified peptide, and SILAC ratio were reported for both MS spectra. c Pie chart describing the CDDP-induced
proteomic changes in NSCLC cells. Upregulated proteins (abundance changes >2-fold increase) are displayed in red; downregulated in blue (abundance
changes <2-fold increase); no change in protein abundance in black. Fragmented proteins are showed in yellow.
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Fig. 3), in agreement with the rule that antibodies generally
recognize the native (folded) proteins rather than the correspond-
ing fragmented (unfolded) forms that, vice versa, are more
efficiently processed and presented to T cells by antigen-
presenting cells (APCs)31, such as those we found upregulated
in apoptotic tumor cells by SILAC-based proteomics.
T effector cell responses to multiple NM-neoAg peptides. To
assess the functional relevance of SILAC findings, we compared
the immunogenicity of proteins resulted fragmented or not in
CDDP-ap or live NSCLC cell line (EpT1Lu). In particular, we
analyzed longitudinally memory T cell responses in peripheral
blood mononuclear cells (PBMCs) isolated from 14 NSCLC (10
LUAD and 4 LUSC) patients, as compared with healthy donors
(HDs), by flow cytometry (FC) (Table 2). All patients showed a
stage IV NSCLC, and four of them had previously experienced a
surgical treatment, without any neo-adjuvant therapy. All patients
were studied before (time 0 [T0]) and after a treatment with
various cycles of a chemotherapy protocol (including CDDP)
(T1), whereas 12 of them were also studied after a subsequent
treatment with several cycles of anti-PD-1 mAb (nivolumab) (T2)
(Table 2). As a control, we also studied memory T cell responses
in PBMCs from seven patients with earlier NSCLC stage (4 with
IIIA, 1 with IIIB, 1 with IIA and 1 with IA), who did not require
neo-adjuvant chemotherapy, and whose blood sample was
obtained immediately before (1 day) the surgery resection (naive
patients) (Supplementary Table 1). The effector (eff) responses
were evaluated by calculating the percentage of CD8+ or CD4+
T cells promptly producing interferon-γ (IFN-γ), tumor necrosis
factor-α (TNF-α), or both ex vivo (i.e., without a previous sti-
mulation in vitro), in response to a peptide matrix composed of
12 peptide pools. Each of these peptide pools contained
6–7 synthetic 20-mer peptides (overlapping of 12 residues),
spanning eight randomly selected proteins that were found
overrepresented in the form of fragmented proteins in CDDP-ap
NSCLC cells, as compared with live NSCLC cells using SILAC-
based MS analysis (i.e., olfactory receptor 5H2; Ras and EF-hand
domain-containing protein; proactivator polypeptide; protein
LYRIC; zinc transporter SLC39A7; ADP/ATP translocase 2;
chatepsin D; ruvB-like 2) (Supplementary Fig. 4a, b). Supporting
that these responses can be defined as effector memory, the
majority of both CD8+ and CD4+ Teff cells specific to the
peptide pools derived from the fragmented proteins (i.e., NM-
neoAgs) were confined within the eff memory CCR7–CD45RA–
(EM) or the CCR7–CD45RA+ (EMRA) cell subsets, rather than
the naive CCR7+CD45RA+ (N) or the central memory CCR7
+CD45RA– (CM) subsets, and were higher in patients than in
HDs, both at T1 (after the chemotherapy protocol including
CDDP) and more at T2 (after the consecutive treatment with
nivolumab), but not at T0 (Figs. 2 and 3). Furthermore, the
majority of responses were higher at both T1 and T2 than at T0,
as well as at T2 as compared with T1, whereas the remaining
Table 1 List of fragmented proteins upregulated by CDDP-treated NSCLC cells in forward and reverse SILAC experiments.
Accession numbera Protein name (gene name)a Peptidesb Late apoptotic/
live ratio
MWcal (kDa)a MWexp range
(kDa)
SILAC forward
P53634 Dipeptidyl peptidase 1 (CTSC) 6 3.5849 51,854 15–20
Q9Y4W6 AFG3-like protein 2 (AFG3L2) 2 2.7856 88,584 15–20
O75844 CAAX prenyl protease 1 homolog (ZMPSTE24) 2 100 54,813 15–20
Q5VTE0 Putative elongation factor 1-alpha-like 3
(EEF1A1P5)
2 1.7272 50,185 15–20
P63261 Actin, cytoplasmic 2 (ACTG1) 2 5.4425 41,793 5–10
O95197 Reticulon-3 (RTN3) 2 2.3429 112,611 15–20
Q9NQC3 Reticulon-4 (RTN4) 1 100 129,931 15–20
Q92504 Zinc transporter SLC39A7 (SLC39A7) 1 11.5738 50,118 15–20
P07686 Beta-hexosaminidase subunit beta (HEXB) 1 2.9101 63,111 15–20
Q16891 Mitochondrial inner membrane protein (IMMT) 1 100 83,678 15–20
Q86UE4 Protein LYRIC (MTGH) 1 100 63,837 5–10
Q8IZ41 Ras and EF-hand domain-containing protein
(RASEF)
1 23.1859 82,879 5–10
P05141 ADP/ATP translocase 2 (SLC25A5) 1 45.9929 32,852 5–10
Q8NGV7 Olfactory receptor 5H2 (OR5H2) 1 1.01 35,974 5–10
P07602 Proactivator polypeptide (PSAP) 1 3.1506 58,133 5–10
P07339 Cathepsin D (CTSD) 1 2.8517 44,552 5–10
SILAC reverse
P53634 Dipeptidyl peptidase 1 (CTSC) 4 8.096 51,854 15–20
Q9NX40 OCIA domain-containing protein-1 (OCIAD1) 3 100 27,626 5–10
P63261 Actin, cytoplasmic 2 (ACTG1) 3 21.9962 41,793 5–10
Q8NGV7 Olfactory receptor 5H2 (OR5H2) 2 100 35,974 5–10
P12236 ADP/ATP translocase 3 (SLC25A6) 2 100 32,866 5–10
Q8IZ41 Ras and EF-hand domain-containing protein
(RASEF)
1 1.9371 82,879 25–30
Q9BQE3 Tubulin alpha-1C chain (TUBA1C) 1 100 49,895 5–10
Q9P0L0 Vesicle-associated membrane protein-associated
protein A (VAPA)
1 100 27,893 5–10
Q9Y230 RuvB-like 2 (RUVBL2) 1 100 51,157 5–10
Q86UE4 Protein LYRIC (MTDH) 1 100 63,837 5–10
P07602 Proactivator polypeptide (PSAP) 1 18.9825 58,113 5–10
Protein fragments identified in both SILAC experiments were highlighted in bold.
aAccession number, gene name and molecular weight (MW) according to Uniprot database.
bNumber of Unique Peptide (C.I. 95%).
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responses tended to be, however, higher at the same times (Figs. 2
and 3). The cumulative responses (magnitude), as calculated by
the means, in all patients tested, of the frequencies of CD8+ and
CD4+ Teff cells promptly producing IFN-γ, TNF-α, or both, in
response to each single peptide pools, were always higher at both
T1 and T2 than at T0, as well as at T2 as compared with T1
(Fig. 4). Notably, both the magnitude and the means of several
CD8+ or CD4+ Teff cell responses against the single NM-neoAg
peptide pools were higher in the subset of naive patients showing
earlier stage tumor and who did not experience any neo-adjuvant
chemotherapy before surgery, as compared with HDs (Fig. 4;
Supplementary Fig. 6). The antigen-specific responses were con-
firmed by dose–curve analyses, supporting that they recognized
antigens with remarkable T cell receptor avidity (Supplementary
Fig. 7). To validate the effector responses against the single
peptides, we compared the percentage of patients showing CD8+
or CD4+ Teff cells producing IFN-γ, TNF-α, or both in response
to the single peptides, at the T1 (after the chemotherapy protocol
including CDDP) and T2 (after the subsequent nivolumab
treatment). The resulting fold change (calculated as the ratio
between percentage of responders among chemotherapy/nivolu-
mab-treated patients, and the percentage of responders among
chemotherapy-treated patients) clearly showed that the multi-
specific responses were more strongly represented upon nivolu-
mab treatment (Supplementary Figs. 8 and 9). Both CD8+ and
CD4+ Teff cells from randomly selected patients studied rapidly
degranulated, in terms of CD107a (a lysosomal-associated
membrane protein-1) mobilization, in response to selected pep-
tide pools derived from NM-neoAgs, whereas those isolated from
HDs were virtually unable to perform these functions ex vivo
(Supplementary Fig. 10). These effector responses were evident
only upon the treatment with either the chemotherapy-alone or
the consecutive nivolumab treatment. In addition, overlapping
peptides derived from some random selected proteins (tubulin
β-4b chain, heterogeneous nuclear ribonucleoprotein A1,
glyceraldehyde-3 phosphate dehydrogenase) that were shown to
be downregulated in CDDP-ap NSCLC cells, and upregulated in
their live cell counterparts in the form of entire proteins, were
also tested (Supplementary Fig. 11a): no significant CD8+ or
CD4+ T cell responses against these peptides were shown in six
patients analyzed, as compared with HDs (Supplementary
Fig. 11b–e). Additional controls showed that the CD8+ or CD4+
Teff cell responses against multiple peptides derived from a
known lung antigen, such as NY-ESO-156,57, increased upon
chemotherapy, and even more upon nivolumab treatments in the
peripheral blood of some patients tested, supporting the possi-
bility that also conventional tumor antigens can be unveiled by
chemotherapy (Supplementary Fig. 12).
Caspase cleavage improves cross-presentation of NM-neoAgs.
To evaluate whether caspases have a role in preparing apoptotic
tumor cell substrate for subsequent processing and presentation
by APCs, we generated CD8+ T cell lines specific to pools con-
taining epitopes (pool 1 and pool 2) related to NM-neoAgs, and
tested them for their capacity to form IFN-γ spots (in an enzyme-
linked immunospot [ELISPOT] assay) within 4–6 h of contact
with autologous monocytes (as APCs) that had been pulsed with:
the relevant peptide pools, CDDP-ap NSCLC cells alone, CDDP-
ap NSCLC cells previously treated with a selective caspase-8
inhibitor (C8I), CDDP-ap NSCLC cells previously treated with a
negative caspase control (K), or lysed NSCLC cells. Both the NM-
neoAg-specific CD8+ T cell lines responded to both the direct
presentation of the relevant peptide pools and the cross-
presentation of CDDP-ap NSCLC cells by APCs, rather than
the cross-presentation of lysed NSCLC cells (representing the
proteome of live tumor cells) (Fig. 5). The treatment of CDDP-ap
NSCLC cells with C8I (but not with K) blocked the cross-
presentation (Fig. 5), validating the hypothesis that chemotherapy
unveiled the related neoAgs by caspase cleavage in apoptotic cells.
APCs that were simultaneously pulsed with C8I-treated apoptotic
tumor cells and peptide pools preserved the capacity to present
the latter, thus ruling out the possibility that apoptotic cells or C8I
could affect the stimulatory capacities of APCs.
Correlation of NM-neoAg-specific T cells with overall survival
and PD-1 decrease. The association between the level of func-
tional Teff cell frequency and overall survival was studied in 12
patients, who experienced the combination of chemotherapy and
immunotherapy protocol, and was computed through the log-
rank (Mantel–Cox) test (Fig. 6). This analysis showed that
patients’ survival was correlated with the capacity of CD8+ Teff
cells, but not CD4+ Teff cells, to produce high IFN-γ or TNF-α
levels in response to NM-neoAgs (one standard deviation above
the average) at T2 (following the nivolumab treatment) (Fig. 6),
Table 2 Demographic and clinical characteristics of NSCLC
patients who experienced CDDP and subsequent nivolumab
treatments.
All CDDP treatment
alone
CDDP and
nivolumab
treatment
Number of patients 14 2/14 12/14
Gender M/F 6/8 1/1 5/7
Age (mean ± SD);
years in range
68 ± 4;
61–77
67 ± 3; 65–68 68 ± 5; 61–77
Tumor histology
LUAD 10/14 2/2 8/12
LUSC 4/14 0/2 4/12
Tumor stage
IV 14/14 2/2 12/12
Mutations
EGFR 1/14 0/2 1/12
ALK 2/14 1/2 1/12
KRAS 2/14 0/2 2/12
Months of overall
survival (mean ±
SD); range
39 ± 21;
9–80
31 ± 24; 14–48 40 ± 21; 9–80
Cycles of
chemotherapy
(mean); rangea
4.8; 3–6 4; 4–4 4.91; 3–6
Cycles of Nivolumab
therapy (mean);
rangeb
24;
3–84
— 24; 3–84
Metastatic progression (instrumental validation)c
Yes 11/14 0/2 11/12
No 1/14 1/2 0/12
NA 2/14 1/2 1/12
Metastatic progression (biochemical validation)d
Yes 8/14 1/2 7/12
No 3/14 0/2 3/12
NA 3/14 1/2 2/12
LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, EGFR epidermal growth factor
receptor, ALK anaplastic lymphoma kinase, KRAS Kirsten rat sarcoma virus, NA not tested.
aA single cycle of CDDP corresponds to 75 mg/m2 administrated every 21 days. In this cohort of
patients, CDDP was administrated in combination with one or more chemotherapeutic drugs
among pemetrexed (500mg/m2), vinorelbine (60mg/m2), docetaxel (75mg/m2), or
gemcitabine (1000mg/m2).
bA single cycle of nivolumab corresponds to 3 mg/kg administered every 14 days.
cInstrumental progression (after chemotherapeutic treatment) evaluated with computed axial
tomography total body or positron emission tomography according to radiologic criteria of
Response Evaluation Criteria in Solid Tumor 1.1.
dBiochemical progression (after chemotherapeutic treatment) evaluated according to increased
levels of tumor biomarkers: carcinoembryonic antigen >5 ng/mL and cancer antigen 15.3 >30
U/mL.
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but not at T1 (after the chemotherapy protocol including CDDP).
No correlation was shown between overall survival and either the
number of chemotherapy or nivolumab cycles received by the
single patients, or the surgery treatment previously performed in
4 out of the 12 patients, who would be submitted to the che-
motherapy/immunotherapy protocol. Interestingly, the follow-up
study showed that the PD-1+ cells within both the NM-neoAg-
specific CD4 and CD8 Teff cells increased upon chemotherapy
(T1), but then they drastically decreased upon the nivolumab
therapy (T2), coming back at the start values (Fig. 7). Notably, the
decrease of the PD-1+ cell percentage at T2 paralleled the pro-
gressive increase of the total CD4+ and CD8+ Teff cells specific
to NM-neoAgs (Fig. 7).
Discussion
In this study, we identified immunogenic neoAgs generated in
chemotherapy-induced apoptotic tumor cells, by combining the
SILAC-based MS technology quantitatively comparing the pro-
teome of primary CDDP-ap and live NSCLC cells, and the “T cell
interrogation system,” by which memory T cells longitudinally
obtained from patients with late NSCLC stage, who would be
submitted to CDDP and nivolumab, were used as a probe to
recognize immunogenic NM-neoAgs58. By this multitask
approach, we provided evidences showing that NM-neoAg-
specific Teff cell responses increased upon chemotherapy, even
more they were boosted by the nivolumab therapy, and correlated
with both patients’ survival and decrease of PD-1 expression.
Our data support the hypothesis that chemotherapy-induced
apoptosis of tumor cells plays a pivotal role in unveiling immu-
nogenic NM-neoAgs, as a result of caspase-dependent proteolytic
activity37,38,42. DCs, upon phagocytosis of immunogenic apop-
totic cells, have been demonstrated to efficiently process caspase-
cleaved cellular fragmented proteins by proteasomes, and then to
cross-present the resulting peptides on major histocompatibility
complex (MHC) molecules priming T cells37,45,48,59. Consistent
with this mechanism, here we show that memory T cells from
NSCLC patients responded to epitopes derived from fragmented
proteins that resulted upregulated in CDDP-ap tumor cells, as
compared with their live counterparts; they did not significantly
Fig. 2 Kinetics of CD8+ Teff cell responses against multiple NM-neoAg epitopes from apoptotic NSCLC cells upon chemotherapy and ICB. a
Representative FC (contour plot) analysis of cytokine production by CD8+ Teff cells in response or not to the peptide pool 6 (derived from the fragmented
proteins found upregulated in CDDP-ap NSCLC cells by SILAC-based MS [see Supplementary Fig. 4]) from a NSCLC patient, detected before (T0), after
chemotherapy (T1), and after nivolumab cycles (T2); NS: non-stimulated cells. The naive (N) cells are indicated as gray dots, the central memory (CM) as
black dots, the effector memory (EM) as blue dots, and the effector memory RA+ (EMRA) as red dots. b Independent FC analyses of CD8+ T cells
producing the indicated cytokines gated within the indicated CD8+ T cell subsets in a representative sample obtained at T1. c–e Percentage of the CD8+
Teff cells producing IFN-γ (c), TNF-α (d), or both (e) in response to the 12 pools of peptides derived from the fragmented proteins upregulated in CDDP-ap
NSCLC cells (as identified by SILAC-based MS). The FC analyses were performed in PBMCs obtained from 14 NSCLC patients before any treatment (T0
N= 6, gray bars), after the chemotherapy cycle (T1 N= 14, red bars), and from 12 of the 14 NSCLC patients after the nivolumab therapy (T2, blue bars), as
well as in PBMCs obtained from 10 HDs (empty bars). Bars were showed as box and whisker graphs; *p < 0.05, **p < 0.01, and ***p < 0.005 by unpaired
Student’s t test.
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respond to peptides derived from entire proteins resulted upre-
gulated in live tumor cells; activation of CD8+ T cell lines specific
to NM-neoAgs was obtained upon cross-presentation of apop-
totic tumor cells (expressing the appropriate fragmented anti-
gens), rather than cross-presentation of lysed tumor cells
(representing the proteome of live tumor cells), and was drasti-
cally reduced by treatment of APCs with caspase inhibitors
in vitro. These observations support the definition of tumor-
associated NM-neoAgs as caspase-cleaved fragments that are
targeted to the processing machinery and cross-presented by
APCs more efficiently than their entire protein counterparts in a
consistent number of patients tested, in analogy with what hap-
pens in the case of (unfolded) DRiPs as compared with the
standard (folded) proteins31. In this context, the wide presence of
effector T cell responses against these apoptosis-related frag-
mented proteins (as detected by ex vivo assays) in the peripheral
blood from several patients upon chemotherapy suggests that
these T cells, to promptly respond ex vivo, had to recently
encounter the corresponding antigens in vivo, supporting the
quality of these tumor-associated fragmented proteins as public
immunogenic NM-neoAgs.
It is interesting to point out that the totality of the immuno-
genic NM-neoAgs identified were overrepresented in CDDP-ap
NSCLC cells as fragmented proteins, as compared with live
NSCLC cells. This finding suggests that these self-Ags are toler-
ated when expressed by live cells in their complete form, but they
would lose the self-identity acquiring that of NM-neoAgs, upon
apoptosis generating caspase-cleaved fragmented proteins
potentially more susceptible to processing and cross-presentation
by APCs. We cannot exclude that other fragmented proteins can
be generated in apoptotic cells by caspase cleavage that are at
subthreshold level for the identification by our SILAC-based MS
approach, or that diverse post-translational pathways can gen-
erate additional neoAgs.
Both NM-neoAg-specific CD8+ and CD4+ Teff cells displayed
a wide range of functions including production of IFN-γ and/or
TNF-α, as well as killing activity in response to the relevant epi-
topes ex vivo. However, the findings that CD8+ Teff cell responses
Fig. 3 Kinetics of CD4+ Teff cell responses against multiple NM-neoAg epitopes from apoptotic NSCLC cells upon chemotherapy and ICB. a
Representative FC (contour plot) analysis of cytokine production by CD4+ Teff cells in response or not to the peptide pool 6 (derived from the fragmented
proteins found upregulated in CDDP-ap NSCLC cells by SILAC-based MS [see Supplementary Fig. 4]) from a NSCLC patient, detected before (T0), after
chemotherapy (T1), and after nivolumab cycles (T2); NS: non-stimulated cells. The naive (N) cells are indicated as gray dots, the central memory (CM) as
black dots, the effector memory (EM) as blue dots, and the effector memory RA+ (EMRA) as red dots. b Independent FC analyses of CD4+ T cells
producing the indicated cytokines gated within the indicated CD4+ T cell subsets in a representative sample obtained at T1. c–e Percentage of the CD4+
Teff cells producing IFN-γ (c), TNF-α (d), or both (e) in response to the 12 pools of peptides derived from the fragmented proteins upregulated in CDDP-ap
NSCLC cells (as identified by SILAC-based MS). The FC analyses were performed in PBMCs obtained from 14 NSCLC patients before any treatment (T0
N= 6, gray bars), after the chemotherapy cycle (T1 N= 14, red bars), and from 12 of the 14 NSCLC patients after the nivolumab therapy (T2, blue bars), as
well as in PBMCs obtained from 10 HDs (empty bars). Bars were shown as box and whisker graphs; *p < 0.05, **p < 0.01, and ***p < 0.005 by unpaired
Student’s t test.
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tended to be wider than the CD4+ Teff responses in patients, and
that only the former correlated with the overall survival suggests
that CD8+ Teff cells provide the principal protective responses
against tumors. On the other hand, we cannot rule out that CD4+
Teff cells can potentially contribute to mediate tumor regres-
sion60–62. In this context, it is not surprising that some CD4+ Teff
cells tested displayed the capacity to degranulate in response to
NM-neoAgs, since cytotoxic CD4+ T cells have been demon-
strated to contribute to immunopathology in various forms of
pathologic conditions, including cancer60,63.
Importantly, NM-neoAgs derived from CDDP-ap tumor cells
were recognized by memory T cells across several HLA-unrelated
patients ex vivo, which in turn correlated with the patients’ sur-
vival. These data suggest that the resulting anti-tumor protection
is likely due to the bystander effect of the wide storm of
inflammatory cytokines produced by Teff cells in response to
cross-presentation of apoptotic tumor cells by tissue-resident
APCs, rather than by the direct killing of tumor cells, requiring an
MHC-restricted antigen recognition on intact cells. In addition,
these Teff cells may provide bystander (indirect) killing of
neighboring live tumor cells in a non-antigen-specific manner64.
Therefore, our system would result advantageous for the identi-
fication of public immunogenic tumor NM-neoAg epitopes
recognized by multiple HLA-mismatched patients. Consistent
Fig. 4 Magnitude of CD8+ or CD4+ Teff cell responses to multiple NM-neoAg epitopes. a, b Each symbol represents the mean of percentage of CD8+
(a) or CD4+ (b) Teff cells producing IFN-γ, TNF-α, or both in response to a single peptide pool (of 12 pools) in PBMCs from HDs (n= 10), naive patients
(n= 7), or in PBMCs obtained from 14 NSCLC patients before any treatment (T0 N= 6), after the chemotherapy cycle (T1 N= 14), and from 12 of the
latter after the nivolumab therapy (T2). Bars were shown as box and whisker graphs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way
ANOVA with Tukey’s multiple comparison test.
Fig. 5 Caspase-dependent cross-presentation of NM-neoAgs from apoptotic NSCLC cells. a, b Responses of CD8+ T cell lines specific to peptide pool 1
(a) or peptide pool 2 (b) derived from NM-neoAgs unveiled in CDDP-ap NSCLC cells, to autologous irradiated monocytes, as APCs, which had been pulsed
or not with the related peptide pools, CDDP-ap (ap.) NSCLC cells, ap. NSCLC cells previously treated with a selective caspase-8 inhibitor (C8I), ap. NSCLC
cells previously treated with a negative caspase control (K), or lysed (Ly.) NSCLC cells. Results represent the mean of two different experiments in
triplicate and are expressed as IFN-γ spots in 2 × 104 lined CD8+ T cells. Bars were shown as box and whisker graphs; *p < 0.05, ***p < 0.005, and ****p <
0.0001 by unpaired Student’s t test.
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with this possibility, recent evidences showed that necroptotic
tumor cells confer tumor control across multiple syngeneic tumor
models54. Although chronic inflammation can promote initial
carcinogenesis by the production of several inflammatory cyto-
kines, including IFN-γ, TNF-α, interleukin-6 (IL-6), and IL-1, in
combination with the production of reactive oxygen or nitrogen
species by activated myeloid cells65–67, the same pro-
inflammatory cytokines released by immune cells in an ICD
milieu can favor immune activation rather than suppression in
the tumor microenvironment, and enable ultimately the immune
Fig. 6 Kaplan–Meier survival curves. a, b Each Kaplan–Meier plot presents NSCLC patients, who experienced the combination of chemotherapy and
nivolumab therapy (i.e., studied at T2 n= 12), in two groups: “high IFN-γ (a) or TNF-α (b)” (blue) with above-average (median value) values of IFN-γ or
TNF-α production in response to NM-neoAgs by CD8+ T cells among all samples, while “low IFN-γ (a) or TNF-α (b)” (gray) with values below average.
Decreased number of live patients in a time point of 10 years is reported below the curves. *p < 0.05 by log-rank (Mantel–Cox) test.
Fig. 7 ICB therapy boosts NM-neoAg-specific CD4+ and CD8+ Teff cell responses in relation with a drastic reduction of PD-1 expression. a, b
Representative FC (contour plot) analysis of PD-1 expression within the total gated CD8+ (a) or CD4+ (b) T cells producing IFN-γ, TNF-α, and both (sum
of antigen-specific CD8+ or CD4+ T cells) to peptide pool 1, 3, or 4. The FC analyses were performed in PBMCs obtained at T0 (before any treatment), T1
(after the chemotherapy treatment), or T2 (after the nivolumab treatment). c, d Each symbol in the left graphs represents the mean of percentage of CD8+
(c) or CD4+ (d) Teff cells producing IFN-γ, TNF-α, or both in response to a single peptide pool (of 12 pools) (here defined as specific CD8+ or CD4+
T cells), whereas each symbol in the right graphs represents the mean of percentage of PD-1+ cells within the specific CD8+ (c) or CD4+ (d) Teff cells.
The FC analyses were performed in PBMCs obtained from 14 NSCLC patients before any treatment (T0 N= 6), after the chemotherapy cycle (T1 N= 14),
and from 11 patients after the nivolumab therapy (T2). Bars were showed as box and whisker graphs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
by two-way ANOVA with Tukey’s multiple comparison test.
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system to act effectively against metastatic tumors67–69. On this
basis, the beneficial effects by checkpoint inhibitors depend on
the presence of a pro-inflammatory “hot” environment70.
The finding that naive patients, who were not submitted to
neo-adjuvant chemotherapy and whose blood sample was
obtained the day before surgery, showed detectable frequencies of
NM-neoAg-specific Teff cells in steady state, as compared with
HDs, leads to the hypothesis that these responses were primed by
tumor cells, made apoptotic by the natural T cell pressure against
tumor progression in the early-stage tumor patients67. Studies on
a large cohort of these patients showing pre-existing memory
NM-neoAg-specific Teff cells would be of interest to verify if they
could benefit from boosting ICB, upon surgery. Previous data
emphasized the requirement of pre-existing memory tumor-
specific T cells for unlashing the anti-tumor responses by the
combination of chemotherapy and ICB or by vaccination71,72.
The finding that these pre-existing memory T cells were almost
undetectable at T0 (before chemotherapy and nivolumab treat-
ments) in our advanced tumor patients supports the idea that
they inevitably decrease in these patients, as a result of T cell
exhaustion by chronic antigen stimulation67. Our data indicate
that they can be reinvigorated following the double chemotherapy
effect (i.e., increasing tumor cell apoptosis generating high levels
of NM-neoAgs, and ICD induction), providing the appropriate
signals (1, 2, 3, etc.) for the boosting of T cell expansion following
checkpoint inhibitors, which ultimately correlates with overall
survival. Whether other ICD forms, including necroptosis
(occurring downstream of the receptor-interacting protein kina-
ses RIPK1 and RIPK3)73, can enable tumor cells to generate
similar or overlapping sets of NM-neoAg repertoire that may
contribute to potentiate anti-tumor immunity54 is a crucial issue
to investigate.
The observation that the percentage of NM-neoAg-specific
CD4+ and CD8+ Teff cells expressing PD-1 increased upon
chemotherapy indicates that NM-neoAgs, generated by
chemotherapy-dependent apoptosis, principally activate and
expand PD-1+ tumor-specific CD4+ and CD8+ T cells, providing
thus the substrate on which anti-PD-1 therapy can perform its
boosting effect directed towards the PD-1+ tumor-specific cell
population14,17. This hypothesis is supported by the evidence
showing that the ICB therapy induced a further increase of the
frequency of NM-neoAg-specific CD4+ and CD8+ Teff cells that
paralleled a drastic reduction of PD-1 expression and correlated
with the overall survival. Consistent with this finding, PD-1
blockade has been proposed to induce a pattern of metabolic and
effector T cell-specific changes that was related with an
enhancement of effector molecules (e.g., IFN-γ and granzymes)
and in a decrease of the exhaustion markers TIM-3 and LAG-314.
In addition, it has been recently demonstrated that PD-1 blockade
counteracts the increase of PD-1high CD4+ T follicular helper
cells that accumulate at the tumor site and inhibits Teff functions
in experimental tumor models74.
Although the follow-up study of a larger cohort of patients is
required to validate the association of patients’ survival with
CD8+ T cell responses to the fragmented proteins identified in
apoptotic tumor cells, an important facet of our study is that
memory T cells targeting shared NM-neoAgs among several
NSCLC patients can be detected in the peripheral blood, and can
potentially be used for developing T cell-based immunotherapy
across multiple cancer patients12.
Methods
Study population. Human studies were performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki and approved by the Institutional
Ethical Committee (No. 2926). Informed consent was obtained from all patients.
Histological diagnosis was determined based on microscopic features of carcinoma
cells. We enrolled and monitored 14 stage IV NSCLC (10 LUAD and 4 LUSC)
patients: all patients were studied before and after various cycles of a chemotherapy
protocol (including CDDP), whereas 12 (8 LUAD and 4 LUSC) of them were also
studied after a subsequent treatment with several cycles with nivolumab (Table 2),
by analyzing longitudinally memory T cell responses to several peptide pools
derived from proteins that had been previously identified as fragmented, or entire
proteins in primary CDDP-ap or live NSCLC line by SILAC-based MS. CDDP
treatment started within the first month after diagnosis in all enrolled patients.
Nivolumab treatment started after failure (demonstrated by instrumental and/or
biochemical metastatic progression) of CDDP chemotherapy. Demographic, clin-
ical, and therapeutic characteristics of these NSCLC patients are described in
Table 2. Possible EGFR and KRAS mutations were detected by Real-Time PCR
(Applied Biosystems 7500, USA). Two out of the 14 patients could not be sub-
mitted to nivolumab after CDDP therapy, because one of them showed an ALK
translocation and underwent oral Crizotinib target therapy, while the other patient
spontaneously left our Oncology Center (Sapienza Università of Rome). As a
control, T cell responses were also studied in PBMCs from seven patients with
earlier stage IV NSCLCs (four with IIIA, one with IIIB, one with IIA, and one with
IA), who did not require neo-adjuvant chemotherapy, and whose blood sample was
obtained immediately before (1 day) the surgery resection (naive patients) (Sup-
plementary Table 1), and in PBMCs from 10 HDs.
Isolation and characterization of NSCLC cells. The NSCLC cell line named
EpT1Lu were established in the Immunology and Immunotherapy Unit of Regina
Elena National Cancer Institute, Rome, and obtained from surgery specimen of a
69-year-old male patient, who underwent curative surgery at the Regina Elena
National Cancer Institute in Rome in 2013 and who were diagnosed with a LUAD
G2 T2ab N1 M0. No genomic aberration of lung cancer-specific genes EGFR and
KRAS was detected in both tissue biopsy and tumor cell line by Real-Time PCR
(Applied Biosystems 7500, USA) using TaqMan (CE-IVD EntroGen Kit). The
patient did not receive preoperative chemotherapy or radiotherapy. Signed
informed consent was obtained from patients. The present study was approved by
the ethics committee of the Regina Elena National Cancer Institute in Rome (CEC/
722/14). Fresh tumor tissue (within 1 h after surgical removal) was washed in
phosphate-buffered saline (PBS, Corning, USA) and minced into small pieces <1
mm3 using a scalpel. The specimen was enzymatically digested by trypsin (Sigma-
Aldrich, USA) at a final concentration of 0.25M for 30 min at 37 °C in a humi-
dified incubator with 5% of CO2. Then, RPMI-1640 with 10% of fetal bovine serum
(FBS, Gibco, USA) was added, and after washing, cells were transferred into a
standard tissue culture plate and cultured in RPMI-1640 with penicillin/strepto-
mycin supplemented with 10% FBS and L-glutamine (Sigma-Aldrich). The cultures
were maintained at 37 °C in a humidified incubator with 5% of CO2. The culture
medium was changed every 2–3 days. Cells were passaged after detachment when
the cells reached 80–90% confluence. All the studies were performed with the initial
five passages. Cell lines of epithelial origin were checked by FC staining of epithelial
cell surface antigen CD326 (Ep-CAM) (Miltenyi Biotec, Germany)75 (Supple-
mentary Fig. 1a), as well as when cell morphology was also consistent with the
epithelial origin (Supplementary Fig. 1b). The cell lines were analyzed for 24
genetic markers using the PowerPlex Fusion System Kit (BMR Genomics s.r.l.,
Italy).
CDDP-dependent apoptosis of NSCLC cells. Primary NSCLC cell lines were
plated (1.5 ×105 cells/well) in 6-well plates and grown overnight. Cells were treated
or not with 2-fold serial dilution of CDDP (from 1.25 to 0.078 μM). Apoptotic cells
were detected by the Annexin V/Fixable Viability Dye (eBioscience, USA) and anti-
active-caspase-3 (BD Biosciences, USA) staining. Each treatment was in duplicate
and three different experiments were performed. After 72 h, cells were harvested,
transferred into flow tubes, pelleted, re-suspended in 100 μL of fresh 1× Fixable
Viability Dye eFluor780 in PBS and incubated for 30 min at room temperature.
Cells were then washed and re-suspended in 100 μL of Annexin binding buffer plus
Annexin V fluorescein isothiocyanate (FITC) for 15 min at room temperature.
Cells were fixed and permeabilized with Cytofix/Cytoperm Kit (BD Biosciences)
and stained with Brillant Violet 450 anti-active-caspase-3 for 20 min at 4 °C. After
staining, samples were acquired by FC within 1 h using an LSRFortessa (BD
Biosciences). Experiments were analyzed with the FlowJo software (TreeStar Inc.,
version 10.1r5) (Supplementary Fig. 1).
SILAC labeling of primary NSCLC cells and sorting. Primary NSCLC cells were
grown in either SILAC heavy (13C615N4-arginine and 13C6-lysine) or SILAC light
(12C614N4-arginine and 12C6-lysine) conditions for eight passages before the first
experiment55. This period lasted about 3 weeks, until the SILAC heavy cells
labeling was complete (SILAC Protein Quantitation Kit, cod. 89982, Life Tech-
nologies, Thermo Fisher Scientific, USA). To analyze a reverse duplicate, NSCLC
cells were also grown in SILAC light or SILAC heavy media, under the same
experimental conditions. Total metabolic incorporations were verified by MS.
Then, cultured NSCLC cells that were metabolically labeled with heavy isotope
medium were induced to apoptosis by 0.625 µM CDDP treatment (72 h). To purify
CDDP-treated apoptotic and live cells for protein identification, NSCLC cells,
grown in heavy and light SILAC media, were labeled with Annexin V FITC/Fixable
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Viability Dye eFluor780 as previously described. Sorting was performed using a
FACSAria III (BD Biosciences) equipped with 488, 561 and 633 nm laser and the
FACSDiva software (version 6.1.3; BD Biosciences). Data were analyzed using the
FlowJo software (TreeStar, USA). Following isolation, an aliquot of the collected
cells was evaluated for purity at the same sorter resulting in an enrichment >90%
for late apoptotic and live cells (Fig. 1a). These fractions were collected, pelleted
and rapidly frozen. Five experiments were performed to obtain the correct protein
amount for SILAC-based MS approach. Equal amounts of protein (100 μg) of
whole-cell extracts from CDDP-treated or -untreated NSCLC cell lines were mixed
and separated on 4–12% gradient gels by SDS-PAGE (NuPAGE bis-tris gel, cod.
NP0335box, Life Technologies, Thermo Fisher Scientific).
NanoLC and MS analyses. Protein digestion, peptide purification, nanoLC ana-
lysis, and MS analysis were performed as previously reported55. Equal protein
amounts (100 μg) of whole-cell extracts from CDDP-treated or -untreated NSCLC
cell lines were mixed and separated on 4–12% gradient gels by SDS-PAGE
(NuPAGE bis-tris gel cod. NP0335box, Life Technologies, Thermo Fisher Scien-
tific, USA). Gels were stained by Simply Blue Safe Stain (cod. LC6065, Life
Technologies, Thermo Fisher Scientific) and 16 sections for each gel lane were cut.
Protein-containing gel pieces were washed with 100 μL of 0.1 M ammonium
bicarbonate (5 min at room temperature [RT]) (cod. A6141, Sigma-Aldrich). Then,
100 μL of 100% acetonitrile (ACN, cod.14261, Sigma-Aldrich) was added to each
tube and incubated for 5 min at RT. The liquid was discarded, the washing step
repeated once more, and the gel plugs were shrunk by adding ACN. The dried gel
pieces were reconstituted with 100 μL of 10 mM DL-dithiothreitol (cod. D5545,
Sigma-Aldrich)/0.1 M ammonium bicarbonate and incubated for 40 min at 56 °C
for cysteine reduction. The excess liquid was then discarded and cysteines were
alkylated with 100 μL of 55 mM iodoacetamide (cod. 16125, Sigma-Aldrich)/0.1 M
ammonium bicarbonate (20 min at RT, in the dark). The liquid was discarded, the
washing step was repeated once more, and the gel plugs were shrunk by adding
ACN. The dried gel pieces were reconstituted with 12.5 ng/μL trypsin (cod. V5111,
Promega Corporation, USA) in 50 mM ammonium bicarbonate and digested
overnight at 37 °C. The supernatant from the digestion was saved in a fresh tube
and 100 μL of 1% trifluoroacetic acid (TFA, cod. 302031 Sigma-Aldrich)/30% ACN
were added on the gel pieces for an additional extraction of peptides. The extracted
solution and digested mixture were then combined and vacuum centrifuged for
organic component evaporation. Peptides were re-suspended with 40 μL of 2.5%
ACN/0.1% TFA, desalted and filtered through a C18 microcolumn ZipTip (cod.
ZTC185096, Millipore Merck, Germany), and eluted from the C18 bed using 10 μL
of 80% ACN/0.1% TFA55. The organic component was once again removed by
evaporation in a vacuum centrifuge and peptides were re-suspended in a suitable
nanoLC injection volume (typically 3–10 μL) of 2.5% ACN/0.1% TFA. An UltiMate
3000 RSLC nanoLC system (Thermo Fisher Scientific) equipped with an integrated
nanoflow manager and microvacuum degasser was used for peptide separation.
The peptides were loaded onto a 75 μm ID NanoSeries C18 column (P/N 164534,
Thermo Fisher Scientific) for multistep gradient elution (eluent A 0.05% TFA;
eluent B 0.04% TFA in 80% ACN) from 5 to 20% eluent B within 10 min, from 20
to 50% eluent B within 45 min and for further 5 min from 50 to 90% eluent B with
a constant flow of 0.3 μL/min. After 5 min, the eluted sample fractions were con-
tinuously diluted with 1.2 μL/min a-cyano-4-hydroxycinnamic acid (cod. C2020,
Sigma-Aldrich) and spotted onto a MALDI target using an HTC-xt spotter (PAL
System, Switzerland) with an interval of 20 s resulting in 168 fractions for each gel
slice. MS Analysis MALDI-TOF-MS spectra were acquired using a 5800 MALDI-
TOF/TOF Analyzer (Sciex, Canada). The spectra were acquired in the positive
reflector mode by 20 subspectral accumulations (each consisting of 50 laser shots)
in an 800–4000 mass range, focus mass 2100 Da, using a 355 nmNb:YAG laser
with a 20 kV acceleration voltage. Peak labeling was automatically done by 4000
Series Explorer software, version 4.1.0 (Sciex) without any kind of smoothing of
peaks or baseline, considering only peaks that exceeded a signal-to noise ratio of 10
(local noise window 200m/z) and a half-maximal width of 2.9 bins. Calibration was
performed using default calibration originated by five standard spots. Only MS/MS
spectra of preselected peaks (out of peak pairs with a mass difference of 6.02, 10.01,
12.04, 16.03, and 20.02 Da) were integrated over 1000 laser shots in the 1 kV
positive ion mode with the metastable suppressor turned on. Air at the medium gas
pressure setting (1.25 × 10−6 Torr) was used as the collision gas in the CID off
mode. After smoothing and baseline subtractions, spectra were generated auto-
matically by the 4000 Series Explorer software. MS and MS/MS spectra were
processed by the ProteinPilot software 4.5 (Sciex), which acts as an interface
between the Oracle database containing raw spectra and a local copy of the
MASCOT search engine (version 2.1; Matrix Science, Boston, USA). The Paragon
algorithm was used with SILAC (Lys+6, Arg+10) selected as the sample type,
iodoacetamide as cysteine alkylation, with the search option “biological modifica-
tions” checked, and trypsin as the selected enzyme. MS/MS protein identification
was performed against the Swiss-Prot database (number of protein sequences:
254757; released on 20121210) without taxon restriction using a confidence
threshold >95% (Proteinpilot Unused score ≥1.31). The monoisotopic precursor
ion tolerance was set to 0.12 Da and the MS/MS ion tolerance to 0.3 Da. The
minimum required peptide length was set to six amino acids. All accepted human
peptides had a false discovery rate of 0.05 using reversed database searches.
Quantitation was based on a two-dimensional centroid of the isotope clusters
within each SILAC pair. Ratios of the corresponding isotope forms in the SILAC
pair were calculated, and lines fitting these intensity ratios gave the slope as the
desired peptide ratio. The MS proteomics data have been deposited to the Pro-
teomeXchange Consortium via the PRIDE76 partner repository with the dataset
identifier PXD016997.
IHC analysis. IHC analysis was performed on serial, formalin-fixed paraffin-
embedded or hematoxylin–eosin-stained sections of cancer tissue samples from
five NSCLC patients, who were submitted to neo-adjuvant (CDDP) therapy before
surgery resection. Antibodies used were: anti-PSAP (Abcam, Cambridge, UK),
anti-LYRIC/AEG1 (Abcam, Cambridge, UK) and anti-cleaved caspase-3 (Cell
Signaling Technology, Danvers, MA) (Supplementary Table 2). The immunor-
eactions were revealed by Bond Polymer Refine Detection (Leica Biosystem, Milan,
Italy) on an automated autostainer (BondTM Max, Leica). The evaluation of the
different proteins was performed independently by two investigators blinded to
clinical data. Apoptotic cells and apoptotic bodies were characterized in
hematoxylin–eosin-stained sections by cell shrinkage, with condensed hyperchro-
matic nuclear chromatin and deeply eosinophilic cytoplasm, and dense extra-
cellular or intracellular chromatin fragments, with or without associated cytoplasm,
respectively. They were visualized by activated caspase-3 staining in formalin-fixed
paraffin-embedded sections.
Synthetic overlapping peptides. Eight fragmented proteins (upregulated in
CDDP-ap NSCLC cells) and three entire proteins (upregulated in live NSCLC cells)
were selected for immunologic validation and analyzed for their amino acid
sequence (Supplementary Figs. 4a and 11a). For each fragment a region of 20
residues before and after MS-identified sequence was selected. For custom synthesis
(Mimotopes Peptide Company, Australia), 37 20-mer peptides with an overlapping
region of 12 amino acids (derived from the eight fragmented proteins), as well as 22
20-mer peptides with an overlapping region of 12 amino acids (derived from the
three entire proteins), were designed, in order to overcome the HLA restrictions
(Supplementary Figs. 4a and 11a). Peptides were pooled into 12 mixtures of a
matrix scheme77, in which each peptide was shared between two pools and used in
experiments of functional validation (Supplementary Fig. 4b). The six to seven
peptides were pooled in order that each single peptide was shared between two
pools according to the matrix scheme (Supplementary Fig. 4a, b). As a control,
multiple overlapping NY-ESO-1 peptides (PepTivator NY-ESO-1 premium grade,
human, Miltenyi Biotec) were used.
Antigen-specific T cell assays and flow cytometry analyses. PBMCs were
isolated from fresh heparinized blood by density gradient centrifugation with
lympholyte (Cedarlane, Canada), and collected in complete RPMI medium con-
taining 10% heat-inactivated FBS (HyClone GE Healthcare Life Sciences, USA),
2 mM L-glutamine (Sigma-Aldrich), penicillin/streptomycin (EuroClone, Italy),
non-essential amino acids (EuroClone), and sodium pyruvate (EuroClone). Cells
were stimulated or not with 20 μg/mL peptide pool plus 1 μg/mL of anti-CD28
mAb (BD Biosciences) and the Protein Transport Inhibitor Cocktail (brefeldin A
and monensin; eBioscience), or with the Cell Stimulation plus Protein Transport
Inhibitor Cocktail (eBioscience) as a positive control, and mAb to CD107a for
degranulation analysis, for 18 h at 37 °C. After antigen stimulation, cells were
washed and stained with Fixable Viability Dye eFluor780 (eBioscience) for the
exclusion of dead cells in PBS and then incubated for 30 min at room temperature.
After washing, surface staining was performed by incubating cells with the labeled
mAbs to CD4, CD8, CCR7, CD45RA, PD-1 and with a cocktail of labeled mAbs to
CD14, CD16, CD56, CD19 (dump channel was included for the exclusion of
monocytes, natural killer cells, and B cells, respectively; antibody details are
reported in Supplementary Table 2) for 20 min at 4 °C in PBS containing 2% FBS.
To analyze cytokine production, cells were fixed and permeabilized using the BD
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) at 4 °C
for 20 min, washed, and stained with mAbs to IFN-γ and TNF-α for 20 min at 4 °C
in BD Perm/Wash buffer (BD Biosciences). As a control, PBMCs from some
patients were also stimulated with multiple peptides derived from NY-ESO-1
(PepTivator NY-ESO-1 premium grade, human, Miltenyi Biotec), by using the
same experimental procedure above. Cells were acquired with LSRFortessa cyt-
ometer (BD Biosciences) and analyzed with the FlowJo software version 10.0.8r1
(TreeStar). Gating strategy is illustrated in Supplementary Fig. 5.
Isolation and expansion of CD8+ T cell lines. Highly purified CD8+ T cells and
monocytes were isolated from a patient’s PBMCs responding to the peptide pools 1
and 2, by magnetic bead separation with the CD8+ T Cell Isolation Kit and Pan
Monocyte Isolation Kit (Miltenyi Biotec), respectively. Antigen-specific CD8+ T
cell lines were obtained upon repeated (bi-weekly) stimulation with autologous
irradiated PBMCs that were previously pulsed with the relevant peptide pools and
expanded in IL-2-conditoned medium, as previously described37,48.
Cross-presentation assay. Fresh NSCLC cells (10 × 106) were cultured in the
presence or absence of 14 μg/mL C8I (ZIETD-FMK) or a negative caspase control
(K, Z-FA-FMK) (BD Biosciences) for 1 h at 37 °C. Then, they were induced to
undergo apoptosis by CDDP treatment and processed for validating apoptosis, as
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described above. Control cells were represented by live NSCLC cells, which were
promptly lysed by repeated freezing and thawing. Highly purified monocytes (3 ×
104), used as APCs, were pulsed with increasing concentrations of C8I-treated, K-
treated, untreated apoptotic NSCLC cells, control lysed cells, or peptides in U-
bottom 96-well plates for 18 h. Then, APCs were cultured with lined antigen-
specific CD8+ T cells (2–3 × 104), and IFN-γ spot formation by CD8+ T cells was
promptly revealed after 6–8 h at 37 °C by an ELISPOT assay, as previously
described37,48. Each peptide pool was tested in triplicate. The HLA restriction of
these responses was demonstrated by blocking responses with an appropriate anti-
class I mAb.
Bioinformatic analysis of SILAC experiment. The over-representation analysis of
down- and upregulated proteins obtained from SILAC analysis was performed
online with PANTHER classification system (version 14.1 – 2018_04 release; http://
www.pantherdb.org). GO analysis within biological process category (cellular
process [level 2] and sub-categories) was evaluated. In particular, enriched genes
for “apoptotic mitochondrial changes – GO:0008637” in mitochondrion organi-
zation category, “response to toxic substance GO:0009636,” and “response to drug
GO:0042493” in response to chemical category were reported only in upregulated
proteins (Supplementary Fig. 2B).
Statistics and reproducibility. Statistical analyses were performed using the
software GraphPad Prism version 6.0h. To compare cytokine production in
response to each single peptide pool among HD, NP, T0, T1, and T2, unpaired
Student’s t test was used. To compare the overall cytokine production in response
to all pools among HD, NP, T0, T1, and T2, one-way analysis of variance
(ANOVA) test with Tukey’s multiple comparison test was used. PD-1 expression
analysis was performed with two-way ANOVA test. Cross-presentation and
dose–response curve analyses were performed with unpaired Student’s t test.
Kaplan–Meier survival curve with log-rank (Mantel–Cox) test was performed to
compare two groups of patients selected by a median cut-off. All statistical analyses
were two tailed. Significance was set at p < 0.05. The number of HDs or patients,
whose PBMCs were submitted to immunologic analyses, were described in the
corresponding figure legends: when PBMCs’ amount was enough, the reproduci-
bility of flow cytometry assay was confirmed by duplicate experiments. Results
obtained in the forward SILAC were found similar in the reverse SILAC, as a
control, thus highlighting a high reproducibility between the SILAC replicates
(Supplementary Fig. 2a; Supplementary Data 1).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data will be available from the authors upon request: A.G. (alessio.
grimaldi@uniroma1.it) will be responsible for proteomics data, and I.C. (Ilenia.
cammarata@uniroma1.it) for immunological data. The MS proteomics data have been
deposited into the ProteomeXchange Consortium via the PRIDE76 partner repository
with the dataset identifier PXD016997. The list of proteins identified in primary NSCLC
cell line by SILAC-based MS is provided in Supplementary Data 1. The source data
underlying the main figures are shown in Supplementary Data 2.
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